Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients ≥ 6 months old~* Diagnosis of cystic fibrosis (CF) based upon the following historical criteria performed prior to study participation:~  1. confirmed sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis (at least 2 tests), OR~ 2. genotype with two identifiable mutations consistent with CF.~* First or early lower respiratory tract infection with Pseudomonas (P.) aeruginosa documented by either of the following:~  1. first infection defined by the first P. aeruginosa isolated from sputum or deep throat cough swab culture, OR~ 2. P. aeruginosa from sputum or deep throat cough swab culture following at least 1 year of negative cultures (documented with at least 4 negative cultures during this year and no positive cultures) and no anti-pseudomonal treatment during this 1-year period, OR~ 3. P. aeruginosa from sputum or deep throat cough swab culture following at least 2 years of negative cultures (documented with at least 2 negative cultures per year and no positive cultures) and no anti-pseudomonal treatment during this 2-year period.~* Written informed consent by the patient and/or parent/legal guardian according to local country regulations.~Exclusion criteria:~* History of aminoglycoside hypersensitivity or adverse reaction to inhaled aminoglycoside.~* Signs and symptoms of acute pulmonary disease, eg, pneumonia, pneumothorax.~* Administration of any investigational drug within 30 days prior to enrollment.~* Administration of loop diuretics within 7 days prior to study drug administration.~* Personal/family history of abnormal hearing, other than typical hearing loss associated with the aging process.~* Abnormal result from an audiology testing (defined as either a unilateral pure-tone audiometry test showing a threshold elevation \> 20 decibels \[dB\] at any frequency across the frequency range 0.25-8 kHz or the absence of emission at the evoked otoacoustic emission test).~* Positive urine pregnancy test at Day 1 (Baseline) for all female patients who have reached menarche.~* Use of macrolide antibiotics as a maintenance therapy for 12 or more days during the 28 days prior to Baseline.~* Antibody titers ≥ 1000 for any of the 3 P. aeruginosa exoenzymes: Exotoxin A, alkaline protease, or elastase (status to be determined between Baseline and Day 28).

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin 300 mg for 28 days (Type: EXPERIMENTAL): Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
- Tobramycin 300 mg for 56 days (Type: EXPERIMENTAL): Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).